↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID21948594.edit
↑Hirst, WD; Stean, TO; Rogers, DC; Sunter, D; Pugh, P; Moss, SF; Bromidge, SM; Riley, G i dr.. (2006). „SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models”. European Journal of Pharmacology553 (1–3): 109–19. DOI:10.1016/j.ejphar.2006.09.049. PMID17069795.
↑Wesołowska, A; Nikiforuk, A (2007). „Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression”. Neuropharmacology52 (5): 1274–83. DOI:10.1016/j.neuropharm.2007.01.007. PMID17320917.
↑Wesołowska, A (2008). „The anxiolytic-like effect of the selective 5-HT6 receptor antagonist SB-399885: the impact of benzodiazepine receptors”. European Journal of Pharmacology580 (3): 355–60. DOI:10.1016/j.ejphar.2007.11.022. PMID18096153.
↑Wesołowska, A; Nikiforuk, A (2008). „The selective 5-HT(6) receptor antagonist SB-399885 enhances anti-immobility action of antidepressants in rats”. European Journal of Pharmacology582 (1–3): 88–93. DOI:10.1016/j.ejphar.2007.12.013. PMID18234190.
↑Li, Z; Huang, M; Prus, AJ; Dai, J; Meltzer, HY (2007). „5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus”. Brain Research1134 (1): 70–8. DOI:10.1016/j.brainres.2006.11.060. PMID17207474.